MAP Pharma reports late-stage migraine success; Indian biotech business booming again;

@FierceBiotech: HHS report underscores big shift to foreign drug trials. Article | Follow @FierceBiotech

 @JohnCFierce:  Regulus inks $750M pact with Sanofi; 25m upfront, 10m in equity and a $50m option thrown in on broader pact. Article | @JohnCFierce

> MAP Pharmaceuticals says that its late-stage migraine therapy Levadex hit all four co-primary endpoints, demonstrating the drug could work regardless of when it was administered during the migraine cycle. The drug also met several secondary endpoints and was well tolerated. MAP release

> An Indian trade group reports that the country's biotech business has tripled its total revenue in the past five years. And Biocon has reclaimed its position as the industry leader. Story

> Santaris Pharma and miRagen Therapeutics have formed a strategic alliance to develop microRNA-targeted medicines for cardiovascular disease. Santaris release

> The Max Planck Society has broken ground in its new, 100,000-square-foot research complex in Florida. The state of Florida and Palm Beach County are investing $181 million in Max Planck. Report

> The FDA has cancelled a panel review of Lux Biosciences' New Drug Application for voclosporin on June 28. Release

> Shares of Bioniche Life Sciences surged after the Canadian biopharma announced a global veterinary license pact with Trophogen, a U.S.-based biotech. Release

And Finally... Psychological scientists have found that the size of different parts of people's brains correspond to their personalities. One example: conscientious people tend to have a bigger lateral prefrontal cortex, a region of the brain involved in planning and controlling behavior. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.